Jonathan Wolleben
Stock Analyst at Citizens JMP
(4.84)
# 401
Out of 4,377 analysts
804
Total ratings
49.8%
Success rate
19.6%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Maintained: Buy | $35 → $12 | $6.76 | +77.51% | 21 | May 19, 2026 | |
| ALT Altimmune | Maintained: Buy | $14 → $11 | $2.71 | +305.90% | 81 | May 14, 2026 | |
| SPRB Spruce Biosciences | Maintained: Buy | $170 → $150 | $50.43 | +197.44% | 28 | May 14, 2026 | |
| IRD Opus Genetics | Maintained: Buy | $12 → $11 | $4.03 | +172.95% | 2 | May 13, 2026 | |
| KLRS Kalaris Therapeutics | Maintained: Buy | $26 → $25 | $4.44 | +463.06% | 3 | May 13, 2026 | |
| PHVS Pharvaris | Maintained: Buy | $52 → $74 | $31.09 | +138.02% | 34 | May 13, 2026 | |
| MBX MBX Biosciences | Maintained: Buy | $61 → $86 | $30.28 | +184.02% | 4 | May 12, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $97 → $95 | $32.92 | +188.58% | 48 | May 8, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintained: Buy | $25 → $28 | $8.41 | +232.94% | 49 | May 7, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | $120 → $137 | $97.38 | +40.69% | 36 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $1.27 | +608.66% | 1 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 → $55 | $16.59 | +231.53% | 44 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $26.95 | - | 16 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $176 → $152 | $86.40 | +75.93% | 21 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.50 | +433.33% | 42 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $120 → $113 | $37.58 | +200.69% | 25 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $140 → $132 | $93.48 | +41.21% | 31 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $63 | $35.37 | +78.12% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $8.25 | - | 63 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.01 | - | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $527 → $745 | $486.98 | +52.98% | 61 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $11 | $5.09 | +116.11% | 17 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.17 | +467.82% | 41 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $4 | $0.7332 | +445.55% | 7 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.31 | - | 53 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $6.63 | n/a | 27 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $15.95 | n/a | 42 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $29.93 | n/a | 1 | May 12, 2023 |
Sagimet Biosciences
May 19, 2026
Maintained: Buy
Price Target: $35 → $12
Current: $6.76
Upside: +77.51%
Altimmune
May 14, 2026
Maintained: Buy
Price Target: $14 → $11
Current: $2.71
Upside: +305.90%
Spruce Biosciences
May 14, 2026
Maintained: Buy
Price Target: $170 → $150
Current: $50.43
Upside: +197.44%
Opus Genetics
May 13, 2026
Maintained: Buy
Price Target: $12 → $11
Current: $4.03
Upside: +172.95%
Kalaris Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $26 → $25
Current: $4.44
Upside: +463.06%
Pharvaris
May 13, 2026
Maintained: Buy
Price Target: $52 → $74
Current: $31.09
Upside: +138.02%
MBX Biosciences
May 12, 2026
Maintained: Buy
Price Target: $61 → $86
Current: $30.28
Upside: +184.02%
Crinetics Pharmaceuticals
May 8, 2026
Maintained: Buy
Price Target: $97 → $95
Current: $32.92
Upside: +188.58%
BioCryst Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $25 → $28
Current: $8.41
Upside: +232.94%
Protagonist Therapeutics
May 6, 2026
Maintained: Buy
Price Target: $120 → $137
Current: $97.38
Upside: +40.69%
May 5, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $1.27
Upside: +608.66%
May 1, 2026
Maintained: Buy
Price Target: $47 → $55
Current: $16.59
Upside: +231.53%
Apr 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $26.95
Upside: -
Mar 17, 2026
Maintained: Buy
Price Target: $176 → $152
Current: $86.40
Upside: +75.93%
Mar 12, 2026
Reiterated: Buy
Price Target: $8
Current: $1.50
Upside: +433.33%
Feb 27, 2026
Maintained: Buy
Price Target: $120 → $113
Current: $37.58
Upside: +200.69%
Feb 26, 2026
Maintained: Buy
Price Target: $140 → $132
Current: $93.48
Upside: +41.21%
Feb 24, 2026
Initiated Coverage: Buy
Price Target: $63
Current: $35.37
Upside: +78.12%
Feb 17, 2026
Maintained: Buy
Price Target: n/a
Current: $8.25
Upside: -
Jan 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.01
Upside: -
Jan 20, 2026
Maintained: Buy
Price Target: $527 → $745
Current: $486.98
Upside: +52.98%
Oct 23, 2025
Maintained: Buy
Price Target: $8 → $11
Current: $5.09
Upside: +116.11%
Oct 6, 2025
Reiterated: Buy
Price Target: $18
Current: $3.17
Upside: +467.82%
Oct 6, 2025
Maintained: Buy
Price Target: $15 → $4
Current: $0.7332
Upside: +445.55%
Jul 17, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.31
Upside: -
May 23, 2025
Reiterated: Buy
Price Target: $19
Current: $6.63
Upside: n/a
Apr 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $15.95
Upside: n/a
May 12, 2023
Maintained: Buy
Price Target: $24
Current: $29.93
Upside: n/a